2020
In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer
Luis de Redín I, Expósito F, Agüeros M, Collantes M, Peñuelas I, Allemandi D, Llabot JM, Calvo A, Irache JM. In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer. Drug Delivery And Translational Research 2020, 10: 635-645. PMID: 32040774, DOI: 10.1007/s13346-020-00722-7.Peer-Reviewed Original ResearchConceptsAlbumin nanoparticlesHuman serum albumin nanoparticlesAlbumin-based nanoparticlesSerum albumin nanoparticlesPoor tumor penetrationNanoparticlesColorectal cancerTumor penetrationFree bevacizumabXenograft modelAdequate carrierMean sizeHT-29 xenograft modelMetabolic tumor volumePotential undesirable side effectsHuman colorectal cancerTumor growth rateConventional formulationUndesirable side effectsLower incidenceTumor volumeBevacizumabEffective treatmentSide effectsVivo efficacy
2017
miR-146a targets c-met and abolishes colorectal cancer liver metastasis
Bleau AM, Redrado M, Nistal-Villan E, Villalba M, Exposito F, Redin E, de Aberasturi AL, Larzabal L, Freire J, Gomez-Roman J, Calvo A. miR-146a targets c-met and abolishes colorectal cancer liver metastasis. Cancer Letters 2017, 414: 257-267. PMID: 29133238, DOI: 10.1016/j.canlet.2017.11.008.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesMiR-146aColorectal cancerPrimary tumorColorectal cancer liver metastasesLiver metastatic variantsMC38 adenocarcinoma cellsCancer liver metastasesCRC patientsMajor complicationsTreatment optionsDisease progressionMouse modelMetastasisMetastatic clonesSerial transplantationAdenocarcinoma cellsGene expression arraysHigh expressionMetastatic variantsDeadliest typesNew targetsMicroRNA profilingExpression levels